the life expectancy and quality of life of individuals with neurodegenerative diseases
through the design of innovative diagnostic systems.
and non-invasive diagnostic tools that can be used
at any stage of the disease.
Early diagnosis
Reliable
Non-invasive
Our goal
To provide neurologists with an integrated diagnostic solution that can be applied to any stage of the disease, including the earliest, asymptomatic phase.
Benefits
- Reduced cost of AD risk-assessment and diagnosis.
- More widespread testing thanks to simpler, more readily available diagnostic methods.
- Improved diagnosis, through earlier detection and differentiation of distinct dementia types.
- Simplified diagnosis through leveraging of existing laboratory equipment.
- Improved patient experience and safety.
The e4Risk® is a non-genetic, cost-effective, and highly reliable method to detect the presence of the ApoE4 protein in human blood plasma using high-throughput chemical analysis.
The AD Dementia test is a multiparametric test that combines the detection and quantification of up to 9 metabolites or proteins in a plasma sample. The input of these measurements into an algorithm provides an accurate diagnosis and classifies the patient as either Alzheimer´s disease or frontotemporal dementia.
The Degenerative dementia test is based on the detection and quantification of up to 7 blood biomarkers that are specifically altered in patients affected by neurodegeneration due to FTD or AD. The DD test is conceived as a “screening” tool for use in clinical practice.
Entrevista: Detectar el riesgo genético de padecer Alzheimer con un análisis de sangre
Hoy por Hoy - Cadena SER | Angels Barceló 27/01/2020
Detectar el riesgo genético de padecer Alzheimer con un análisis de sangre
SOCIEDAD / TERESA RUBIO - Cadena SER 27/01/2018 La empresa biotecnológica española Biocross ha desarrollado un test con el que, a través de una simple analítica de sangre, se puede averiguar el factor de riesgo genético de una persona a padecer Alzheimer. Este...
El SERGAS adjudica a Biocross un proyecto de compra de innovación tecnológica enfocado a soluciones en el campo del envejecimiento
El SERGAS ha adjudicado a Biocross S.L. el contrato de compra de innovación tecnológica para el desarrollo de servicios de I+D para el diagnóstico precoz en pacientes con patologías relacionadas con neurología, por un importe de 223.000€ dentro del plan de innovación...
If you have any questions or comments, we will be pleased to attend you
If you have any questions or comments,
we will be pleased to attend you
Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain
+34 983 54 98 96
